Atheroprotective Effects of High-Density Lipoproteins

Annual Review of Medicine

Volumn 54, Issue , 2003, Pages 321-341

  Assmann, Gerd ^a   Nofer, Jerzy Roch ^a  

^a UNIVERSITY OF MÜNSTER   (Germany)

Author keywords

ABCA1; Arteriosclerosis; High density lipoproteins (HDL); Lipoprotein oxidation; Lysosphingolipids; Reverse cholesterol transport

Indexed keywords

1 ALKYL 2 ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; ABC TRANSPORTER; ABC TRANSPORTER A1; ALITRETINOIN; ANTILIPEMIC AGENT; ANTIOXIDANT; APOLIPOPROTEIN A1; ARYLDIALKYLPHOSPHATASE; CHOLESTEROL ESTER TRANSFER PROTEIN; FIBRIC ACID DERIVATIVE; GREEN FLUORESCENT PROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 8; LIPID; LIPOPROTEIN; LYSOSPHINGOLIPID; NICOTINIC ACID; OXYSTEROL; UNCLASSIFIED DRUG; VASCULAR CELL ADHESION MOLECULE 1; HIGH DENSITY LIPOPROTEIN;

ATHEROSCLEROSIS; CELL PROTECTION; CHOLESTEROL TRANSPORT; CLINICAL OBSERVATION; CORONARY RISK; ENDOTHELIUM LESION; HUMAN; IN VITRO STUDY; IN VIVO STUDY; INHIBITION KINETICS; ISCHEMIC HEART DISEASE; LIPOPROTEIN METABOLISM; MOLECULAR MECHANICS; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN FUNCTION; REVERSE CHOLESTEROL TRANSPORT; REVIEW; RISK ASSESSMENT; TRANSGENIC MOUSE; ANIMAL; ARTERIOSCLEROSIS; BLOOD; CORONARY ARTERY ATHEROSCLEROSIS; PATHOPHYSIOLOGY; RISK FACTOR; TRANSGENIC ANIMAL; VASCULAR ENDOTHELIUM;

ANIMALS; ANIMALS, GENETICALLY MODIFIED; ARTERIOSCLEROSIS; CHOLESTEROL, HDL; CORONARY ARTERIOSCLEROSIS; ENDOTHELIUM, VASCULAR; HUMANS; LIPOPROTEINS, HDL; RISK FACTORS;

EID: 0038798094     PISSN: 00664219     EISSN: None     Source Type: Book Series    
DOI: 10.1146/annurev.med.54.101601.152409     Document Type: Review

References (83)

1. Genest J Jr, Marcil M, Denis M, Yu L. 1999. High density lipoproteins in health and in disease. J. Investig. Med. 47:31-42
2. von Eckardstein A, Nofer J-R, Assmann G. 2001. High density lipoproteins and arteriosclerosis. Role of cholesterol efflux and reverse cholesterol transport. Arterioscler. Thromb. Vasc. Biol. 21:13-27
3. Shah PK, Kaul S, Nilsson J, Cercek B. 2001. Exploiting the vascular protective effects of high-density lipoprotein and its apolipoproteins: an idea whose time for testing is coming, part I. Circulation 104:2376-83
4. Shah PK, Kaul S, Nilsson J, Cercek B. 2001. Exploiting the vascular protective effects of high-density lipoprotein and its apolipoproteins: an idea whose time for testing is coming, part II. Circulation 104:2498-502
5. von Eckardstein A, Nofer JR, Assmann G. 2000. Acceleration of reverse cholesterol transport. Curr. Opin. Lipidol. 15:348-54
6. von Eckardstein A, Nofer JR, Assmann G. 2001. High density lipoproteins and arteriosclerosis. Role of cholesterol efflux and reverse cholesterol transport. Arterioscler. Thromb. Vasc. Biol. 21:13-27
7. Kalopissis AD, Chambaz J. 2000. Transgenic animals with altered high-density lipoprotein composition and functions. Curr. Opin. Lipidol. 11:149-53
8. Fielding CJ, Fielding PE. Cellular cholesterol efflux. 2001. Biochim. Biophys. Acta 1533:175-89
9. Yokoyama S. 2000. Release of cellular cholesterol: molecular mechanism for cholesterol homeostasis in cells and in the body. Biochim. Biophys. Acta 1529:231-44
10. Gu X, Kozarsky K, Krieger M. 2000. Scavenger receptor class B, type I-mediated [3H]cholesterol efflux to high and low density lipoproteins is dependent on lipoprotein binding to the receptor. J. Biol. Chem. 275:29993-30001
11. Fielding PE, Nagao K, Hakamata H, et al. 2000. A two-step mechanism for free cholesterol and phospholipid efflux from human vascular cells to apolipoprotein A-1. Biochemistry 39:14113-20
12. Ioannou YA. 2001. Multidrug permeases and subcellular cholesterol transport. Nat. Rev. Mol. Cell. Biol. 2:657-68
13. Assmann G, von Eckardstein A, Brewer HB. 1995. Familial high density lipoprotein deficiency: Tangier disease. In The Metabolic and Molecular Bases of Inherited Diseases, ed. CR Scriver, AL Beaudet, WS Valle, D Sly, pp. 2053-72. New York: McGraw-Hill
14. Rust S, Walter M, Funke H, et al. 1998. Assignment of Tangier disease to chromosome 9q31 by a graphical linkage exclusion strategy. Nat. Genet. 20:96-98
15. Brooks-Wilson A, Marcil M, Clee SM, et al. 1999. Mutations in ABC1 in Tangier disease and familial high-density lipoprotein deficiency. Nat. Genet. 22:336-45
16. Bodzioch M, Orso E, Klucken J, et al. 1999. The gene encoding ATP-binding cassette transporter 1 is mutated in Tangier disease. Nat. Genet. 22:347-51
17. Rust S, Rosier M, Funke H, et al. 1999. Tangier disease is caused by mutations in the gene encoding ATP-binding cassette transporter 1. Nat. Genet. 22:352-55
18. Oram JF, Lawn RM, Garvin MR, Wade DP. 2000. ABCA1 is the cAMP-inducible apolipoprotein receptor that mediates cholesterol secretion from macrophages. J. Biol. Chem. 275:34508-11
19. Wang N, Silver DL, Costet P, Tall AR. 2000. Specific binding of apoA-I, enhanced cholesterol efflux, and altered plasma membrane morphology in cells expressing ABC1. J. Biol. Chem. 275:33053-58
20. Wang N, Silver DL, Thiele C, Tall AR. 2001. ATP-binding cassette transporter A1 (ABCA1) functions as a cholesterol efflux regulatory protein. J. Biol. Chem. 276:23742-47
21. Bortnick AE, Rothblat GH, Stoudt G, et al. 2000. The correlation of ATP-binding cassette 1 mRNA levels with cholesterol efflux from various cell lines. J. Biol. Chem. 275:28634-40
22. Orso E, Broccardo C, Kaminski WE, et al. 2000. Transport of lipids from Golgi to plasma membrane is defective in Tangier disease patients and Abc1-deficient mice. Nat. Genet. 24:192-96
23. Hamon Y, Broccardo C, Chambenoit O, et al. 2000. ABC1 promotes engulfment of apoptotic cells and transbilayer redistribution of phosphatidylserine. Nat. Cell Biol. 2:399-406
24. Fitzgerald ML, Mendez AJ, Moore KJ, et al. 2001. ATP-binding cassette transporter A1 contains an NH2-terminal signal anchor sequence that translocates the protein's first hydrophilic domain to the exoplasmic space. J. Biol. Chem. 276:15137-45
25. Bungert S, Molday LL, Molday RS. 2001. Membrane topology of the ATP binding cassette transporter ABCR and its relationship to ABC1 and related ABCA transporters: identification of N-linked glycosylation sites. J. Biol. Chem. 276: 23539-46
26. Chambenoit O, Hamon Y, Marguet D, et al. 2001. Specific docking of apolipoprotein A-I at the cell surface requires a functional ABCA1 transporter. J. Biol. Chem. 276:9955-60
27. Zha X, Genest J Jr, McPherson R. 2001. Endocytosis is enhanced in Tangier fibroblasts: possible role of ATP-binding cassette protein A1 in endosomal vesicular transport. J. Biol. Chem. 276:39476-83
28. Mendez AJ, Lin G, Wade DP, et al. 2001. Membrane lipid domains distinct from cholesterol/sphingomyelin-rich rafts are involved in the ABCA1-mediated lipid secretory pathway. J. Biol. Chem. 276:3158-66
29. Kamp D, Sieberg T, Haest CW. 2001. Inhibition and stimulation of phospholipid scrambling activity. Consequences for lipid asymmetry, echinocytosis, and microvesiculation of erythrocytes. Biochemistry 40:9438-46
30. Drobnik W, Borsukova H, Bottcher A, et al. 2002. Apo AI/ABCA1-dependent and HDL3-mediated lipid efflux from compositionally distinct cholesterol-based microdomains. Traffic 3:268-78
31. Szakacs G, Langmann T, Ozvegy C, et al. 2001. Characterization of the ATPase cycle of human ABCA1: implications for its function as a regulator rather than an active transporter. Biochem. Biophys. Res. Commun. 288:1258-64
32. Neufeld EB, Remaley AT, Demosky SJ, et al. 2001. Cellular localization and trafficking of the human ABCA1 transporter. J. Biol. Chem. 276:27584-90
33. Tsukamoto K, Hirano Ki, Tsujii Ki, et al. 2001. ATP-binding cassette transporter-1 induces rearrangement of actin cytoskeletons possibly through Cdc42/N-WASP. Biochem. Biophys. Res. Commun. 287: 757-65
34. Hirano K, Matsuura F, Tsukamoto K, et al. 2000. Decreased expression of a member of the Rho GTPase family, Cdc42Hs, in cells from Tangier disease - the small G protein may play a role in cholesterol efflux. FEBS Lett. 484:275-79
35. Lin G. 2002. Insights of high-density lipoprotein apolipoprotein- mediated lipid efflux from cells. Biochem. Biophys. Res. Commun. 291:727-31
36. Erickson JW, Zhang C, Kahn RA, et al. 1996. Mammalian Cdc42 is a brefeldin A-sensitive component of the Golgi apparatus. J. Biol. Chem. 27:26850-54
37. Chen W, Sun Y, Welch C, et al. 2001. Preferential ATP-binding cassette transporter A1-mediated cholesterol efflux from late endosomes/lysosomes. J. Biol. Chem. 276:43564-69
38. Holtta-Vuori M, Maatta J, Ullrich O, et al. 2000. Mobilization of late-endosomal cholesterol is inhibited by Rab guanine nucleotide dissociation inhibitor. Curr. Biol. 10:95-98
39. Von Eckardstein A, Langer C, Engel T, et al. 2001. ATP binding cassette transporter ABCA1 modulates the secretion of apolipoprotein E from human monocyte-derived macrophages. FASEB J. 15:1555-61
40. McNeish J, Aiello RJ, Guyot D, et al. 2000. High density lipoprotein deficiency and foam cell accumulation in mice with targeted disruption of ATP-binding cassette transporter-1. Proc. Natl. Acad. Sci. USA 97:4245-50
41. Aiello RJ, Brees D, Bourassa PA, et al. 2002. Increased atherosclerosis in hyperlipidemic mice with inactivation of ABCA1 in macrophages. Arterioscler. Thromb. Vasc. Biol. 22:630-37
42. Cavelier LB, Qiu Y, Bielicki JK, et al. 2001. Regulation and activity of the human ABCA1 gene in transgenic mice. J. Biol. Chem. 276:18046-51
43. Vaisman BL, Lambert G, Amar M, et al. 2001. ABCA1 overexpression leads to hyperalphalipoproteinemia and increased biliary cholesterol excretion in transgenic mice. J. Clin. Invest. 108:303-9
44. Joyce CW, Amar MJ, Lambert G, et al. 2002. The ATP binding cassette transporter A1 (ABCA1) modulates the development of aortic atherosclerosis in C57BL/6 and apoE-knockout mice. Proc. Natl. Acad. Sci. USA 99:407-12
45. Haghpassand M, Bourassa PA, Francone OL, Aiello RJ. 2001. Monocyte/ macrophage expression of ABCA1 has minimal contribution to plasma HDL levels. J. Clin. Invest. 108:1315-20
46. van Eck M, Bos IS, Kaminski WE, et al. 2002. Leukocyte ABCA1 controls susceptibility to atherosclerosis and macrophage recruitment into tissues. Proc. Natl. Acad. Sci. USA 99:6298-303
47. O'Connell BJ, Genest J Jr. 2001. High-density lipoproteins and endothelial function. Circulation 104:1978-83
48. Spieker LE, Sudano I, Hurlimann D, et al. 2002. High-density lipoprotein restores endothelial function in hypercholesterolemic men. Circulation 105:1399-402
49. Cockerill GW, Huehns TY, Weerasinghe A, et al. 2001. Elevation of plasma high-density lipoprotein concentration reduces interleukin-1-induced expression of E-selectin in an in vivo model of acute inflammation. Circulation 103:108-12
50. Dimayuga P, Zhu J, Oguchi S, et al. 1999. Reconstituted HDL containing human apolipoprotein A-1 reduces VCAM-1 expression and neointima formation following periadventitial cuff-induced carotid injury in apoE null mice. Biochem. Biophys. Res. Commun. 264:465-68
51. -/- mice. FASEB J. 14:2032-39
52. Li D, Weng S, Yang B, et al. 1999. Inhibition of arterial thrombus formation by ApoA1 Milano. Arterioscler. Thromb. Vasc. Biol. 19:378-83
53. Yuhanna IS, Zhu Y, Cox BE, et al. 2001. High-density lipoprotein binding to scavenger receptor-BI activates endothelial nitric oxide synthase. Nat. Med. 7:853-57
54. Li XA, Titlow WB, Jackson BA, et al. 2002. High density lipoprotein binding to scavenger receptor, Class B, type I activates endothelial nitric-oxide synthase in a ceramide-dependent manner. J. Biol. Chem. 277:11058-63
55. Cockerill GW, McDonald MC, Mota-Filipe H, et al. 2001. High density lipoproteins reduce organ injury and organ dysfunction in a rat model of hemorrhagic shock. FASEB J. 15:1941-52
56. Nofer JR, Levkau B, Wolinska I, et al. 2001. Suppression of endothelial cell apoptosis by high density lipoproteins (HDL) and HDL-associated lysosphingolipids. J. Biol. Chem. 276:34480-85
57. Xia P, Vadas MA, Rye KA, et al. 1999. High density lipoproteins (HDL) interrupt the sphingosine kinase signaling pathway. A possible mechanism for protection against atherosclerosis by HDL. J. Biol. Chem. 274:33143-47
58. Kimura T, Sato K, Kuwabara A, et al. 2001. Sphingosine 1-phosphate may be a major component of plasma lipoproteins responsible for the cytoprotective actions in human umbilical vein endothelial cells. J. Biol. Chem. 276:31780-85
59. Nofer JR, Fobker M, Hobbel G, et al. 2000. Activation of phosphatidylinositol-specific phospholipase C by HDL-associated lysosphingolipid. Involvement in mitogenesis but not in cholesterol efflux. Biochemistry 39:15199-207
60. Fukushima N, Ishii I, Contos JJ, et al. 2001. Lysophospholipid receptors. Annu. Rev. Pharmacol. Toxicol. 41:507-34
61. Cullen P, Schulte H, Assmann G. 1998. Smoking, lipoproteins and coronary heart disease risk. Data from the Munster Heart Study (PROCAM). Eur. Heart J. 19:1632-41
62. Nofer JR, Kehrel B, Fobker M, et al. 2002. HDL and arteriosclerosis: beyond reverse cholesterol transport. Atherosclerosis 161:1-16
63. Bowry VW, Stanley KK, Stocker R. 1992. High density lipoprotein is the major carrier of lipid hydroperoxides in human blood plasma from fasting donors. Proc. Natl. Acad. Sci. USA 89:10316-20
64. Garner B, Waldeck AR, Witting PK, et al. 1998. Oxidation of high density lipoproteins. Evidence for direct reduction of lipid hydroperoxides by methionine residues of apolipoproteins A-I and A-II. J. Biol. Chem. 273:6088-95
65. Navab M, Hama SY, Anantaramaiah GM, et al. 2000. Normal high density lipoprotein inhibits three steps in the formation of mildly oxidized low density lipoprotein. Steps 2 and 3. J. Lipid. Res. 41:1495-508
66. Navab M, Berliner JA, Subbanagounder G, et al. 2001. HDL and the inflammatory response induced by LDL-derived oxidized phospholipids. Arterioscler. Thromb. Vasc. Biol. 21:481-88
67. Ahmed Z, Ravandi A, Maguire GF, et al. 2001. Apolipoprotein A-I promotes the formation of phosphatidylcholine core aldehydes that are hydrolyzed by paraoxonase (PON-1) during high density lipoprotein oxidation with a eroxynitrite donor. J. Biol. Chem. 276:24473-81
68. Shih DM, Gu L, Hama S, et al. 1996. Genetic-dietary regulation of serum paroxonase expression and its role in atherogenesis in a mouse model. J. Clin. Invest. 97:1630-39
69. Mackness M, Bouillier A, Hennuyer N, et al. 2000. Paraoxonase activity is reduced by a pro-atherosclerotic diet in rabbits. Biochem. Biophys. Res. Commun. 269:232-36
70. Hedrick CC, Hassan K, Hogh GP, et al. 2000. Short-term feeding of atherogenic diet results in reduction of HDL and paraoxonase that may be mediated by an immune mechanism. Arterioscler. Thromb. Vasc. Biol. 20:1946-52
71. Shih DM, Gu L, Xia Y-R, et al. 1998. Mice lacking serum paraoxonase are susceptible to organophosphate toxicity and atherosclerosis. Nature 394:284-87
72. Shih DM, Xia YR, Wang XP, et al. 2000. Combined serum paraoxonase knockout/ apolipoprotein E knockout mice exhibit increased lipoprotein oxidation and atherosclerosis. J. Biol. Chem. 275:17527-35
73. Oda MN, Bielicki JK, Ho TT, et al. 2002. Paraoxonase 1 overexpression in mice and its effect on high-density lipoproteins. Biochem. Biophys. Res. Commun. 290:921-27
74. Durrington PN, Mackness B, Mackness MI. 2001. Paraoxonase and atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 21:473-80
75. Quarck R, De Geest B, Stengel D, et al. 2001. Adenovirus-mediated gene transfer of human platelet-activating factor-acetylhydrolase prevents injury-induced neointima formation and reduces spontaneous atherosclerosis in apolipoprotein E-deficient mice. Circulation 103:2495-500
76. Rubins HB, Robins SJ, Collins D, et al. 1999. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high density lipoprotein cholesterol. Veteran Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N. Engl. J. Med. 341:410-18
77. Schwartz K, Lawn RM, Wade DP. 2000. ABC1 gene expression and apo A-I-mediated cholesterol efflux are regulated by LXR. Biochem. Biophys. Res. Commun. 274:794-802
78. Venkateswaran A, Lafitte BA, Joseph SB, et al. 2000. Control of cellular cholesterol efflux by the nuclear oxysterol receptor LXRalpha. Proc. Natl. Acad. Sci. 97:12097-102
79. Luo Y, Tall AR. 2000. Sterol upregulation of human CETO expression in vitro and in transgenic mice by an LXR element. J. Clin. Invest. 105:513-20
80. Cao G, Beyer TP, Yang XP, et al. 2002. Phospholipid transfer protein is regulated by liver X receptors in vivo. J. Biol. Chem. (epub ahead of print)
81. Repa JJ, Berge KE, Pomajzl C, et al. 2002. Regulation of ATP-binding casette sterol transporters ABCG5 and ABCG8 by the liver X receptors alpha and beta. J. Biol. Chem. 277:18793-800
82. Joseph SB, McKilligin E, Pei L, et al. 2002. Synthetic LXR ligand inhibits the development of atherosclerosis in mice. Proc. Natl. Acad. Sci. 99:7604-9
83. Barter P. 2000. CETP and atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 20:2029-31